Efficacy and Safety of Nitazoxanide for Post Exposure Prophylaxis of COVID-19
Status:
Not yet recruiting
Trial end date:
2020-08-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the efficacy of the drug nitazoxanide 600
mg, administered three times a day, in relation to placebo in preventing the development of
COVID-19 in subjects from vulnerable communities that had direct contact with patients
diagnosed with the disease.